CN118021632A - Composition for promoting differentiation or proliferation of human adipose-derived stem cells - Google Patents

Composition for promoting differentiation or proliferation of human adipose-derived stem cells Download PDF

Info

Publication number
CN118021632A
CN118021632A CN202410183350.XA CN202410183350A CN118021632A CN 118021632 A CN118021632 A CN 118021632A CN 202410183350 A CN202410183350 A CN 202410183350A CN 118021632 A CN118021632 A CN 118021632A
Authority
CN
China
Prior art keywords
acid
extract
sodium
skin
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410183350.XA
Other languages
Chinese (zh)
Inventor
李善珠
金米娜
金美善
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LG H&H Co Ltd
Original Assignee
LG Household and Health Care Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020180109108A external-priority patent/KR102311011B1/en
Priority claimed from KR1020190029998A external-priority patent/KR102199678B1/en
Application filed by LG Household and Health Care Ltd filed Critical LG Household and Health Care Ltd
Priority claimed from CN201980055771.1A external-priority patent/CN112638357B/en
Publication of CN118021632A publication Critical patent/CN118021632A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Zoology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The present invention relates to the use of a cosmetic composition for increasing skin elasticity and improving wrinkles, comprising as an active ingredient one or more substances selected from the group consisting of sodium guaiac acid, acetyl mandelic acid, lacic acid, and palmitoamide.

Description

Composition for promoting differentiation or proliferation of human adipose-derived stem cells
The present application is a divisional application with the application number 201980055771.1, the application date 2019, 8-23, and the name of "composition for promoting differentiation or proliferation of human adipose-derived stem cells".
Technical Field
The present invention relates to a cosmetic composition comprising as an effective ingredient one or more selected from the group consisting of formononetin (Formononetin), emodin (Emodin), atpasin C (Artepillin C), carnosic acid (Carnosic acid), palmitoamide (PALMITAMIDE), guaiacol sodium sulfonate (Sodium Guaiazulene Sulfonate), caffeic acid (CAFFEIC ACID), acetylmandelic acid (ACETYL MANDELIC ACID), lachrymic acid (LACCAIC ACID), ubiquinone (Ubiquinone), hydroxycinnamic acid (Hydroxycinnamic Acid), lutein (Xanthophyll), raspberry ketone (rasberry ketone), gallic acid (GALLIC ACID), terpineol), mannitol sodium phosphate (sodium mannose phosphate), tolhenone (tropolone), glycyrrhetinic acid (GLYCYRRHETINIC ACID), lanosterol, riboflavin sodium phosphate (sodium riboflavin phosphate), menadione (menadione), lipoic acid (thioctic acid), lactoflavin (lactoflavin), onion extract, rice bran extract, bamboo extract, carrot extract, hibiscus extract, magnolia extract, aloe extract and fractions of the extract as well as an improving skin-active ingredient, a cosmetic composition for improving skin cell proliferation, a cosmetic composition for improving wrinkles, a cosmetic composition for human, a skin-cell-type skin-proliferation, a cosmetic composition for improving skin-cell-proliferation, a cosmetic composition for skin-or a cosmetic composition for improving skin cell-proliferation, a cosmetic composition for skin is used in a cosmetic composition for skin or a cosmetic and a method of increasing skin elasticity comprising the step of administering the composition to an individual other than a human.
Background
Adipose tissue together with muscle is responsible for the support function of the skin structure and is an important cell in the skin structure, and the number of adipocytes is only 30 to 40% in number, but accounts for around 90% in volume. It is known that subcutaneous adipose tissue decreases with aging of individuals, whereby the elasticity of skin decreases, and many wrinkles are generated. In addition, when fat is reduced due to rapid weight loss, there is a possibility that the elasticity of the face is reduced and wrinkles are increased. Thus, increasing the volume within the skin by adjusting the amount of adipose tissue that plays an important role in maintaining structures within the skin may be a way to improve skin elasticity and wrinkles. However, in the case of fat transplantation surgery currently used to improve the elasticity of the skin, the following problems arise: the survival rate of transplanted stem cells in living bodies is very low, a re-operation is required after a certain time, transplanted fat clusters, etc. Therefore, it is necessary to study a substance capable of enhancing the structure of the subcutaneous fat layer without such an operation.
However, in the case of the existing technology of directly injecting adipose-derived stem cells, safety problems may occur, and in the case of the technology of mimicking the components secreted during cell culture and providing them to the skin, there is a limitation in that it is difficult to imitate according to actual components. In addition, the cell activity of human adipose-derived stem cells decreases with aging of skin, so that the time required for proliferation increases by more than twice (Gerontolog 2011; 57:66-75), whereby there is a problem in that the reactivity of adipose stem cells present in aging skin is greatly reduced relative to other application techniques. Therefore, it is necessary to study a substance capable of activating subcutaneous adipose tissue by promoting proliferation of adipose stem cells while not irritating the skin.
In addition, in the skin, the lips are susceptible to environmental factors such as ultraviolet rays, coldness, dryness, etc., because they repeatedly contract and expand, not only at the most moving part of the body, but also always exposed to extreme environments. Furthermore, the lips are weak in their own defenses due to their structure different from that of general skin, and their volume decreases with aging, and wrinkles increase, thereby losing attractive shapes. Thus, there is a need to develop a composition having excellent effects on the lips, such as on general skin, for the care of wrinkles, however, there are only techniques to directly use wrinkle-improving components for the research of facial skin, and techniques to impart temporary volume increase. The latter phenomenon of increasing volume has a limitation that it causes a stimulus response (korean laid-open publication No. 10-2012-0140450A).
In recent years, in studies related to adipocytes or fat transplantation, adipose-derived stem cells existing in subcutaneous adipose tissues and having the ability to differentiate into adipocytes have received attention. This is because it is well known that adipocyte factor (adipokine) secreted by adipose-derived stem cells not only increases collagen synthesis in the dermis but also affects skin regeneration. In the case of known substances for differentiating existing fat precursor cells into fat cells, since the fat precursor cells of white rats are targeted, the efficiency is relatively low when applied to stem cells derived from human fat.
Disclosure of Invention
Problems to be solved by the invention
The present inventors have made a hard effort to find a substance capable of effectively promoting the differentiation of adipose-derived stem cells into adipocytes or the proliferation of adipose-derived stem cells, as a result of a substance capable of promoting the process of differentiation of human adipose-derived stem cells into adipocytes, formononetin (Formononetin), emodin (Emodin), atraprin C (Artepillin C), carnosic acid (Carnosic acid), palmitoamide (PALMITAMIDE), guaiacol sodium sulfonate (Sodium Guaiazulene Sulfonate), caffeic acid (CAFFEIC ACID), acetyl mandelic acid (ACETYL MANDELIC ACID), lachrymic acid (LACCAIC ACID), ubiquinone (Ubiquinone), hydroxycinnamic acid (Hydroxycinnamic Acid), xanthophylls (Xanthophyll), raspberry ketone (rasberry ketone), gallic acid (GALLIC ACID), terpineol, sodium mannose phosphate (sodium mannose phosphate), tolhenone (tropolone), glycyrrhetinic acid (GLYCYRRHETINIC ACID), lanosterol (lanosterol), sodium riboflavin phosphate (sodium riboflavin phosphate), menaquinone (menadione), lipoic acid (thioctic acid), lactoflavin (lactoflavin), onion extract, rice bran extract, bamboo extract, carrot extract, hibiscus extract, magnolia bark extract or aloe extract, and it was confirmed that the substances can be used for the purpose of increasing skin elasticity and improving wrinkles, thereby completing the present invention.
Technical proposal for solving the problems
An object of the present invention is to provide a cosmetic composition for improving wrinkles and an effective composition for improving wrinkles, comprising one or more selected from the group consisting of formononetin (Formononetin), emodin (Emodin), actellin C (Artepillin C), carnosic acid (Carnosic acid), palmitoyl amide (PALMITAMIDE), guaiacol sodium sulfonate (Sodium Guaiazulene Sulfonate), caffeic acid (CAFFEIC ACID), acetyl mandelic acid (ACETYL MANDELIC ACID), lachrymal acid (LACCAIC ACID), ubiquinone (Ubiquinone), hydroxycinnamic acid (Hydroxycinnamic Acid), xanthophylls (Xanthophyll), raspberry ketone (rasberry ketone), gallic acid (GALLIC ACID), terpineol), sodium mannose phosphate (sodium mannose phosphate), tolhenone (tropolone), glycyrrhetinic acid (GLYCYRRHETINIC ACID), lanosterol (lanosterol), sodium riboflavin phosphate (sodium riboflavin phosphate), menaquinone (menadione), lipoic acid (thioctic acid), lactoflavin (lactoflavin), onion extract, rice bran extract, bamboo extract, carrot extract, magnolia bark extract, aloe extract and fractions of the extracts.
Another object of the present invention is to provide a food composition for increasing skin elasticity and improving wrinkles, comprising one or more selected from the group consisting of formononetin, emodin, atpirin C, carnosic acid, palmitoamide, guaiacol sodium sulfonate, caffeic acid, acetyl mandelic acid, lacic acid, ubiquinone, hydroxycinnamic acid, xanthophylls, magnolia extract, aloe extract, fractions of magnolia extract, and fractions of aloe extract as an active ingredient.
Another object of the present invention is to provide a pharmaceutical composition for increasing skin elasticity and improving wrinkles, comprising as an active ingredient one or more selected from the group consisting of formononetin, emodin, actellin C, carnosic acid, palmitomide, guaiacol sodium sulfonate, caffeic acid, acetyl mandelic acid, lachrymic acid, ubiquinone, hydroxycinnamic acid, xanthophylls, raspberry ketone (Raspberry ketone), gallic acid (GALLIC ACID), terpineol, sodium mannose phosphate (sodium mannose phosphate), tolhenone (tropolone), glycyrrhetinic acid (GLYCYRRHETINIC ACID), lanosterol (lanosterol), riboflavin sodium phosphate (sodium riboflavin phosphate), menaquinone (menadione), lipoic acid (thioctic acid), lactoflavin (lactoflavin), onion extract, rice bran extract, bamboo extract, carrot extract, hibiscus extract, magnolia bark extract, aloe extract and fractions of the extracts.
Another object of the present invention is to provide a pharmaceutical composition for external use for increasing skin elasticity and improving wrinkles, comprising as an active ingredient one or more selected from the group consisting of formononetin, emodin, actellin C, carnosic acid, palmitomide, guaiacol sodium sulfonate, caffeic acid, acetylmandelic acid, laccaic acid, ubiquinone, hydroxycinnamic acid, xanthophylls, raspberry ketone (Raspberry ketone), gallic acid (GALLIC ACID), terpineol, sodium mannose phosphate (sodium mannose phosphate), tolhenone (tropolone), glycyrrhetinic acid (GLYCYRRHETINIC ACID), lanosterol, riboflavin sodium phosphate (sodium riboflavin phosphate), menaquinone (menadione), lipoic acid (thioctic acid), lactoflavin (lactoflavin), onion extract, rice bran extract, bamboo extract, carrot extract, hibiscus extract, magnolia bark extract, aloe extract and fractions of the extracts.
Still another object of the present invention is to provide a composition for promoting differentiation of human adipose-derived stem cells, comprising as an active ingredient one or more selected from the group consisting of formononetin, emodin, actellin C, carnosic acid, palmitomide, guaiacol sodium sulfonate, caffeic acid, acetylmandelic acid, laccaic acid, ubiquinone, hydroxycinnamic acid, xanthophylls, raspberry ketone (Raspberry ketone), gallic acid (GALLIC ACID), terpineol, sodium mannose phosphate (sodium mannose phosphate), tolhenone (tropolone), glycyrrhetinic acid (GLYCYRRHETINIC ACID), lanosterol, sodium riboflavin phosphate (sodium riboflavin phosphate), menaquinone (menadione), lipoic acid (thioctic acid), lactoflavin (lactoflavin), onion extract, rice bran extract, bamboo extract, carrot extract, hibiscus extract, magnolia bark extract, aloe extract and fractions of the extracts.
It is a further object of the present invention to provide a method of increasing skin elasticity comprising the step of administering said composition to an individual other than a human.
Effects of the invention
The composition of the present invention enhances the structure of subcutaneous fat layer, increases skin elasticity, and improves wrinkles by promoting differentiation of human fat-derived stem cells into adipocytes or promoting proliferation of human fat-derived stem cells, thereby being capable of being used for anti-aging purposes.
Drawings
Fig. 1 shows the result of staining lipid in differentiated adipocytes with oil red O after treating stem cells derived from human fat with formononetin, acetyl mandelic acid, and magnolia bark extract.
Figure 2 shows quantitatively the relative differentiation rates of human fat-derived stem cells treated with formononetin, emodin, atpasin C, carnosic acid, palmitoamide, guaiacol sodium sulfonate, caffeic acid, acetyl mandelic acid, lacic acid, ubiquinone, hydroxycinnamic acid, lutein, magnolia bark extract and aloe vera extract.
Fig. 3 shows the results of comparison of magnolia bark extract with persons who improve canthus wrinkles and lip wrinkles.
Fig. 4a shows the persistence of improvement of lip wrinkles up to week 12 for subject 1 when treated with magnolia bark extract, and fig. 4b shows the persistence of improvement of lip wrinkles up to week 12 for subject 2.
FIG. 5 shows the results of comparing the wrinkle improvement rates of the canthus and the lips of Magnolia officinalis extract and asiaticoside as the existing wrinkle-improving material.
Fig. 6 shows the cell activity rates in human fat-derived stem cells treated with raspberry ketone, gallic acid, caffeic acid, carnosic acid, terpineol, sodium mannose phosphate, tolhenone, glycyrrhetinic acid, lanosterol, riboflavin sodium phosphate, menaquinone, lipoic acid, lactoflavins, lutein, onion, rice bran, bamboo, carrot and hibiscus extract.
Detailed Description
Hereinafter, this will be specifically described. Meanwhile, the respective descriptions and embodiments disclosed in the present application may also be applied to the respective other descriptions and embodiments. That is, all combinations of the various elements disclosed in the application are within the scope of the application. The scope of the present application should not be construed as being limited to the following specific description.
An aspect of the present invention provides a cosmetic composition for improving wrinkles and comprising as an effective ingredient skin-improving material, one or more selected from the group consisting of formononetin (Formononetin), emodin (Emodin), actellin C (Artepillin C), carnosic acid (Carnosic acid), palmitoyl amide (PALMITAMIDE), guaiacol sodium sulfonate (Sodium Guaiazulene Sulfonate), caffeic acid (CAFFEIC ACID), acetyl mandelic acid (ACETYL MANDELIC ACID), lachrymal acid (LACCAIC ACID), ubiquinone (Ubiquinone), hydroxycinnamic acid (Hydroxycinnamic Acid), xanthophylls (Xanthophyll), raspberry ketone (rasberry ketone), gallic acid (GALLIC ACID), terpineol), mannitol sodium mannose phosphate (sodium mannose phosphate), tolhenone (tropolone), glycyrrhetinic acid (GLYCYRRHETINIC ACID), lanosterol (lanosterol), riboflavin sodium phosphate (sodium riboflavin phosphate), menaquinone (menadione), lipoic acid (thioctic acid), lactoflavin (lactoflavin), onion extract, rice bran extract, bamboo extract, carrot extract, hibiscus extract, magnolia bark extract, aloe extract and fractions of the extracts. The composition may contain 1,2,3,4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 of the substances as an active ingredient.
In addition, another embodiment of the present invention provides a cosmetic composition for increasing skin elasticity and improving wrinkles, comprising formononetin, emodin, actelin C, carnosic acid, palmitoamide, guaiacol sodium sulfonate, caffeic acid, acetyl mandelic acid, laccaic acid, ubiquinone, hydroxycinnamic acid, raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tolhenone, glycyrrhetinic acid, lanosterol, riboflavin sodium phosphate, menaquinone, lipoic acid, lactoflavin or a cosmetically acceptable salt of lutein as an active ingredient.
In the present invention, the "cosmetically acceptable salt" is in the form of formononetin, emodin, atpiclin C, carnosic acid, palmitamide, guaiacol sodium sulfonate, caffeic acid, acetyl mandelic acid, laccaic acid, ubiquinone, hydroxycinnamic acid, raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tolhenone, glycyrrhetinic acid, lanosterol, sodium riboflavin phosphate, menaquinone, lipoic acid, lactoflavin or a salt of lutein with other substances, which means a substance capable of exhibiting similar activity to the compound in cosmetics, but is not limited thereto.
As a result of the diligent effort to develop substances capable of activating and restoring the aged subcutaneous fat layer, the inventors of the present invention developed the following substances capable of promoting differentiation of human fat-derived stem cells into adipocytes and proliferation of human fat-derived stem cells: formononetin, emodin, actelin C, carnosic acid, palmitoyl amide, guaiacol sodium sulfonate, caffeic acid, acetyl mandelic acid, lachrymic acid, ubiquinone, hydroxycinnamic acid, xanthophylls, raspberry ketone (Raspberry ketone), gallic acid (GALLIC ACID), terpineol, sodium mannose phosphate (sodium mannose phosphate), tolhenone (tropolone), glycyrrhetinic acid (GLYCYRRHETINIC ACID), lanosterol, sodium riboflavin phosphate (sodium riboflavin phosphate), menaquinone (menadione), lipoic acid (thioctic acid), lactoflavin (lactoflavin), onion extract, rice bran extract, bamboo extract, carrot extract, hibiscus extract, magnolia bark extract, aloe vera extract. It was thus found that a composition comprising said substance can be used as a cosmetic composition for increasing skin elasticity and improving wrinkles. The effect of the substances to increase skin elasticity and improve wrinkles is not known at all so far, which is of great importance from the aspect of the initial development by the present inventors.
The term "formononetin (Formononetin)" of the present invention has a molecular formula of C 16H12O4 and a molecular weight of 284.26, and can be represented by the following chemical formula 1.
[ Chemical formula 1]
The formononetin of the present invention may be isolated from plants including licorice, but is not limited to the method of obtaining it, and may be chemically synthesized by methods known in the art, or may be commercially available.
The term "emodin (Emodin)" of the present invention has a molecular formula of C 15H10O5 and a molecular weight of 270.24, and can be represented by the following chemical formula 2.
[ Chemical formula 2]
The emodin of the present invention is not limited to the method of obtaining the emodin, and a chemically synthesized emodin by a method known in the art may be used, or a commercially available emodin may be used.
The term "atpirin C (Artepillin C)" of the present invention has a molecular formula of C 19H24O3 and a molecular weight of 300.40, and can be represented by the following chemical formula 3.
[ Chemical formula 3]
The method of obtaining the actirin C of the present invention is not limited, and a substance chemically synthesized by a method known in the art may be used, or a commercially available substance may be used.
The term "carnosic acid (Carnosic acid)" of the present invention has a molecular formula of C 20H28O4 and a molecular weight of 332.44, and can be represented by the following chemical formula 4.
[ Chemical formula 4]
The carnosic acid of the present invention is not limited to the method of obtaining it, and a substance chemically synthesized by a method known in the art may be used, or a commercially available substance may be used.
The term "palmitoyl amide (PALMITAMIDE)" of the present invention may be a linear fatty acid amide having 16 carbon atoms, having a molecular formula of C 16H33 NO and a molecular weight of 255, and may be represented by the following chemical formula 5.
[ Chemical formula 5]
The palmitoamide of the present invention is not limited to the method of obtaining the palmitoamide, and a palmitoamide chemically synthesized by a method known in the art may be used, or a palmitoamide commercially available palmitoamide may be used.
The term "guaiac sodium azulene sulfonate (Sodium Guaiazulene Sulfonate)" of the present invention has the molecular formula of C 15H17NaO3 S and molecular weight of 300.35, which can be represented by the following chemical formula 6.
[ Chemical formula 6]
The sodium guaiacol sulfonate of the present invention is not limited to the method for obtaining it, and a substance chemically synthesized by a method known in the art may be used, or a commercially available substance may be used.
The term "caffeic acid (CAFFEIC ACID)" of the present invention has a molecular formula of C 9H8O4 and a molecular weight of 180.157, and can be represented by the following chemical formula 7.
[ Chemical formula 7]
The caffeic acid of the present invention is not limited to the method of obtaining the same, and a substance chemically synthesized by a method known in the art may be used, or a commercially available substance may be used.
Specifically, the term "acetylmandelic acid (ACETYL MANDELIC ACID)" of the present invention may be "O-acetylmandelic acid (O-ACETYL MANDELIC ACID)", which has a molecular formula of C 10H10O4 and a molecular weight of 194.186, and may be represented by the following chemical formula 8.
[ Chemical formula 8]
The acetyl mandelic acid of the present invention is not limited to the method of obtaining the same, and a chemically synthesized substance by a method known in the art may be used, or a commercially available substance may be used.
The term "lac acid (LACCAIC ACID)" according to the present invention is one of natural anthraquinones, which is a dark red crystal produced by coagulating the secretion of lac worm (LACCIFER LACCA KERR), and is well known to be mainly used as a dye. The lac acid may be lac acid a, lac acid B, lac acid C, lac acid D, lac acid E or lac acid F, but is not particularly limited thereto. In one embodiment of the present invention, 50506 (Natural red 25) from Sigma-Aldrich is used as the lacic acid.
The lac acid of the present invention is not limited to the method of obtaining it, and a chemically synthesized substance by a method known in the art may be used, or a commercially available substance may be used.
The term "ubiquinone (Ubiquinone)" of the present invention is one of fat-soluble quinones, which is a constituent factor of the electron transfer system of mitochondria. Specifically, the ubiquinone may be ubiquinone (10), but is not limited thereto, in which case it has a molecular formula of C 59H90O4 and a molecular weight of 863.37, and may be represented by the following chemical formula 9.
[ Chemical formula 9]
The ubiquinone of the present invention is not limited to the method of obtaining it, and a substance chemically synthesized by a method known in the art may be used, or a commercially available substance may be used.
The term "hydroxycinnamic acid (Hydroxycinnamic Acid)" according to the present invention has the molecular formula of C 9H8O3 and the molecular weight of 164.158, and may be isomers (o-, m-, p-hydroxycinnamic acid: ortho-, meta-, and para-hydroxycinnamic acids) each including a different position based on an-OH group directly substituted on a benzene ring and isomers (cis-coumaric acid (coumarinic acid) and trans-coumaric acid (coumaric acid)) different from each other depending on a double bond, and specifically, m-coumaric acid (m-Coumaric acid), but is not particularly limited thereto. The hydroxycinnamic acid may be represented by the following chemical formula 10.
[ Chemical formula 10]
The hydroxycinnamic acid according to the present invention is not limited to the method for obtaining it, and a substance chemically synthesized by a method known in the art may be used, or a commercially available substance may be used.
The term "xanthophylls (Xanthophyll)" in the present invention is an oxycarotenoid pigment of carotenoids present in green parts of plants such as leaves, flowers and fruits, and is represented by yellow color, and has a molecular formula of C 40H56O2 and a molecular weight of 569. Specifically, the xanthophylls may be lutein (lutein), and may be represented by the following chemical formula 11.
[ Chemical formula 11]
The xanthophylls or xanthophylls of the present invention are not limited to the method of obtaining them, and materials chemically synthesized by methods known in the art may be used, or commercially available materials may be used.
The term "Raspberry ketone" according to the present invention has a molecular formula of C 10H12O2 and a molecular weight of 164.20, and can be represented by the following chemical formula 12.
[ Chemical formula 12]
The raspberry ketone of the present invention is not limited to the method of obtaining the raspberry ketone, and a material chemically synthesized by a method known in the art may be used, or a commercially available material may be used.
The term "gallic acid (GALLIC ACID)" of the present invention has a molecular formula of C 7H6O5 and a molecular weight of 170.12, and can be represented by the following chemical formula 13.
[ Chemical formula 13]
The gallic acid of the present invention is not limited to the method for obtaining the gallic acid, and a substance chemically synthesized by a method known in the art may be used, or a commercially available substance may be used.
The term "terpineol" of the present invention has a molecular formula of C 10H18 O and a molecular weight of 154, and can be represented by the following chemical formula 14.
[ Chemical formula 14]
The terpineol of the present invention is not limited to the method of obtaining the same, and a material chemically synthesized by a method known in the art may be used, or a commercially available material may be used.
The molecular formula of the mannose sodium phosphate (sodium mannose phosphate) is C 6H12O9 PNa, and the molecular weight is 282.12. Specifically, the mannose sodium phosphate may be mannose sodium 6-phosphate or D-mannose sodium 6-phosphate (D-Mannose-6-phosphate sodium salt), but is not limited thereto, and the mannose sodium phosphate may be represented by the following chemical formula 15.
[ Chemical formula 15]
The sodium mannose phosphate of the present invention is not limited to the method for obtaining the same, and a substance chemically synthesized by a method known in the art may be used, or a commercially available substance may be used.
The term "tolenone (tropolone)" of the present invention has a molecular formula of C 7H6O2 and a molecular weight of 122, and can be represented by the following chemical formula 16.
[ Chemical formula 16]
The tolterone of the present invention is not limited to the method of obtaining the same, and a chemically synthesized material by a method known in the art may be used, or a commercially available material may be used.
The term "glycyrrhetinic acid (GLYCYRRHETINIC ACID)" of the present invention has a molecular formula of C 30H46O4 and a molecular weight of 471, and can be represented by the following chemical formula 17.
[ Chemical formula 17]
The glycyrrhetinic acid of the present invention is not limited to the method of obtaining it, and a chemically synthesized substance by a method known in the art may be used, or a commercially available substance may be used.
The term "lanosterol" of the present invention has a molecular formula of C 30H50 O and a molecular weight of 427, and can be represented by the following chemical formula 18.
[ Chemical formula 18]
The lanosterol of the present invention is not limited to the method of obtaining it, and a substance chemically synthesized by a method known in the art may be used, or a commercially available substance may be used.
The term "riboflavin sodium phosphate (sodium riboflavin phosphate)" of the present invention has a molecular formula of C 17H20N4NaO9 P and a molecular weight of 478.33, and can be represented by the following chemical formula 19.
[ Chemical formula 19]
The riboflavin sodium phosphate according to the present invention is not limited to the method for obtaining it, and a substance chemically synthesized by a method known in the art may be used, or a commercially available substance may be used.
The term "menaquinone (menadione)" of the present invention is a yellow crystal as one of vitamin K, and has a molecular formula of C 11H8O2 and a molecular weight of 172.18, which can be represented by the following chemical formula 20.
[ Chemical formula 20]
The menaquinone of the present invention is not limited to the method of obtaining the menaquinone, and a chemically synthesized substance by a method known in the art may be used, or a commercially available substance may be used.
The term "lipoic acid (thioctic acid)" of the present invention, also called lipoic acid (lipoic acid), has a molecular formula of C 8H14O2S2 and a molecular weight of 206, and may be represented by the following chemical formula 21.
[ Chemical formula 21]
The lipoic acid or lipoic acid of the present invention is not limited to the method of obtaining the same, and materials chemically synthesized by methods known in the art may be used, or commercially available materials may be used.
The term "lactoflavin (lactoflavin)" in the present invention refers to riboflavin (vitamin B 2(vitamin B2) isolated from milk. The molecular formula of the lactoflavin of the present invention is C 17H20N4O6, the molecular weight is 376.36, and the lactoflavin can be represented by the following chemical formula 22.
[ Chemical formula 22]
The lactoflavin of the present invention is not limited to the method of obtaining it, and a substance chemically synthesized by a method known in the art may be used, or a commercially available substance may be used.
The formononetin, emodin, actellin C, carnosic acid, palmitoamide, guaiacol sodium sulfonate, caffeic acid, acetyl mandelic acid, lacc acid, ubiquinone, hydroxycinnamic acid, raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tolhenone, glycyrrhetinic acid, lanosterol, riboflavin sodium phosphate, menaquinone, lipoic acid, lactoflavin or lutein may exist not only in solvated form, but also in unsolvated (unsolvated) form. In addition, the compounds may exist in crystalline or amorphous forms, all of which are included within the scope of the present invention.
In addition, it is apparent that the scope of the compound includes not only the compound but also its cosmetically acceptable salt, pharmaceutically acceptable salt, and pharmaceutically acceptable salt.
The term "onion (Allium cepa)" of the present invention is a two-year-old herb of the family liliaceae of the order liliaceae, monocotyledonous plants, comprising quercetin, chromium, allicin and the like as main ingredients, and is well known for its anti-inflammatory, blood glucose regulating and blood pressure lowering effects. The onion may be purchased from commercial sales, may be harvested from nature or cultivated, and may be used without limitation as root, stem, leaf, etc.
The term "rice bran" as used herein refers to a pulverized mixture of pericarp, seed coat, aleurone layer, etc. produced when brown rice is milled to make polished rice, and contains inorganic substances such as vitamins B1, B2, niacin, etc. oryzanol, tocopherol, phytic acid, etc. for reducing cholesterol in blood, antioxidative, anticancer, etc. effects are well known.
The term "bamboo (Bambusoideae)" of the present invention is a evergreen perennial plant belonging to the subfamily of the gramineae of the order gramineae of monocotyledonous plants, and is well known in the art of antioxidant, bactericidal, anticancer effects and the like in chinese medicine. The bamboo may be purchased from commercial sales, or extracted from nature or cultivated, and root, stem, leaf, etc. may be used without limitation.
The term "carrot (Daucus carota var. Sativa)" according to the present invention is a two-year-old herb of the family Umbelliferae of the order of the dicotyledon, and comprises β -carotene, lycopene, etc. as main ingredients, and is well known for having effects of antioxidation, anti-aging, and immunity improvement, etc. The carrot may be purchased from commercial sales, or extracted from nature or cultivated, and root, stem, leaf, etc. may be used without limitation.
The term "Hibiscus (Rose of China, hibiscus)" in the present invention means a plant belonging to the genus Hibiscus of the family Malvaceae of the order Malvaceae, which is a dicotyledonous plant, is known to be rich in Hibiscus acid, hydroxycitric acid, etc. for the effect of preventing obesity, etc. The hibiscus can be purchased from commercial sales, extracted from nature or cultivated, and root, stem, leaf, etc. can be used without limitation.
The term "magnolia officinalis (Magnoliae Cortex)" of the present invention is a dried stem or root bark of magnolia officinalis tree of magnoliaceae, comprising lignans and essential oil components as main active ingredients. It is well known that magnolia bark has anti-inflammatory, analgesic, smooth muscle regulating, antiulcer and other effects. The magnolia bark may be purchased from commercial sales, may be harvested from nature or cultivated, and may be used without limitation.
The term "Aloe (Aloe vera)" according to the present invention is a perennial plant belonging to the genus Aloe of the family liliaceae, also known as Aloe vera. The aloe contains aloin, aloe-emodin, aloe tincture, aloe-minozine, etc. as main active ingredients, and is well known for antibacterial, antifungal, antitumor, etc. effects. The aloe may be purchased from commercial sales without limitation, or extracted from nature or cultivated.
The term "extract" in the present invention means a liquid phase component obtained by immersing a target substance in various solvents and then extracting the same for a predetermined time at normal temperature, low temperature or in a heated state, a solid powder obtained by removing the solvent from the liquid phase component, and the like. Furthermore, in addition to the products, it is also to be interpreted openly as including all dilutions of the products, concentrates of the products, crude and purified products of the products, etc.
In the present invention, the extract may be an extract of onion, rice bran, bamboo, carrot, hibiscus, magnolia bark or aloe. The extract may be extracted from various organs of natural plants, hybrid plants, and variety plants, for example, not only from roots, aerial parts, stems, leaves, flowers, trunk of fruits, epidermis of fruits, but also from plant tissues. The extract can be obtained by extraction with water or various organic solvents or the like. In this case, the organic solvent to be used is not particularly limited as long as it can obtain an extract, and may be specifically water, a polar solvent or a nonpolar solvent, more specifically water, a lower alcohol having 1 to 6 carbon atoms (methanol, ethanol, propanol, butanol, or the like), a polyhydric alcohol such as glycerin, butanediol, a hydrocarbon solvent such as methyl acetate, ethyl acetate, or the like, or a mixed solvent thereof, more specifically water, a lower alcohol, 1, 3-butanediol, or a mixed solvent thereof.
The method for obtaining the extract is not particularly limited as long as the onion, rice bran, bamboo, carrot, hibiscus, magnolia bark or aloe extract can be obtained, and specifically, the root, stem, leaf, fruit, flower, dried product and processed product thereof and the like of magnolia bark or aloe can be immersed in the solvent, and then extracted using a method such as cold extraction method, heating extraction method, ultrasonic extraction method by applying ultrasonic waves, reflux extraction method using a reflux cooler and the like.
The term "fraction" in the present invention means a product obtained by performing fractionation to separate a specific component or a specific group of components from a mixture containing various constituent components. In the present invention, the fraction may be a fraction of onion extract, rice bran extract, bamboo extract, carrot extract, hibiscus extract, magnolia bark extract or aloe extract.
In the present invention, the fractionation method for obtaining the fraction is not particularly limited, and may be performed according to a method commonly used in the art, as long as it can exhibit the effects of increasing skin elasticity and improving wrinkles. For example, there may be a solvent fractionation method by treating various solvents, an ultrafiltration fractionation method by passing through an ultrafiltration membrane having a predetermined molecular weight cut-off, a chromatography fractionation method by performing various chromatography (for separation according to size, charge, hydrophobicity or hydrophilicity), a combination of these methods, and the like.
In the present invention, the type of the fractionation solvent used to obtain the fraction is not particularly limited, and any solvent known in the art may be used. As non-limiting examples of the fractionation solvent, there may be mentioned polar solvents such as water, distilled water, alcohols, etc.; nonpolar solvents such as hexane (Hexan), ethyl acetate (ETHYL ACETATE), chloroform (Chloroform), methylene chloride (Dichloromethane), and the like. These fractionation solvents may be used alone or two or more kinds may be mixed for use. In the case of using the alcohol in the fractional distillation solvent, a C1 to C4 alcohol may be used.
In the cosmetic composition of the present invention, one or more selected from the group consisting of formononetin, emodin, actirin C, carnosic acid, palmitoamide, guaiacol sodium sulfonate, caffeic acid, acetyl mandelic acid, lachrymic acid, ubiquinone, hydroxycinnamic acid, xanthophylls, raspberry ketone (rasberry ketone), gallic acid (GALLIC ACID), terpineol (terpineol), sodium mannose phosphate (sodium mannose phosphate), tolhenone (tropolone), glycyrrhetinic acid (GLYCYRRHETINIC ACID), lanosterol (lanosterol), sodium riboflavin phosphate (sodium riboflavin phosphate), menaquinone (menadione), lipoic acid (thioctic acid), lactoflavin (lactoflavin), onion extract, rice bran extract, bamboo extract, carrot extract, hibiscus extract, magnolia bark extract, aloe extract, fractions of magnolia bark extract, and aloe extract may be contained in an amount of 0.0001 to 10 wt% (specifically, not limited thereto) to 0.001 wt% (w/w) to 0.001 wt%). In the case of less than 0.0001 wt%, the effect is very small, whereas in the case of 2 wt% or more, a problem of generating cytotoxicity may occur.
In the present invention, the cosmetic material composition is capable of promoting differentiation of human fat-derived stem cells (Human adipose DERIVED STEM CELL) into adipocytes or proliferation of human fat-derived stem cells. That is, the cosmetic composition may be a composition capable of increasing skin elasticity and improving wrinkles by promoting differentiation of human fat-derived stem cells into adipocytes, or promoting proliferation of human fat-derived stem cells.
The term "stem cells derived from human fat (human adipose DERIVED STEM CELL)" in the present invention is stem cells that can be extracted from human adipose tissue, and refers to pluripotent cells (Multipotent cell) that can differentiate into various cells of the body. Adipose-derived stem cells are present in subcutaneous adipose tissue and have the ability to differentiate into adipocytes. It is well known that the adipocyte factor (adipokine) secreted by adipose-derived stem cells not only increases collagen synthesis in the dermis layer of the skin, but also affects skin regeneration.
The term "adipocytes (adipose cell)" of the present invention refers to cells for storing fat in adipose tissue of an individual, and specifically, may refer to white adipocytes (white adipoytes) present in subcutaneous fat layers, but is not limited thereto.
In one embodiment of the present invention, it was confirmed that the differentiation of human fat-derived stem cells into adipocytes was effectively promoted as a result of the treatment of human fat-derived stem cells with formononetin, emodin, atpidlin C, carnosic acid, palmitoyl amide, guaiac sodium sulfonate, caffeic acid, acetyl mandelic acid, lacc acid, ubiquinone, hydroxycinnamic acid, xanthophylls, magnolia officinalis extract and aloe extract. Thus, the composition of the present invention comprising the substance can be used for anti-aging purposes by increasing skin elasticity and improving wrinkles.
In one embodiment of the present invention, it was confirmed that the proliferation of human fat-derived stem cells was promoted by significantly increasing the cell activity rate of human fat-derived stem cells compared to the control group as a result of treating human fat-derived stem cells with raspberry ketone, gallic acid, caffeic acid, carnosic acid, terpineol, mannitol sodium phosphate, tolenone, glycyrrhetinic acid, lanosterol, riboflavin sodium phosphate, menaquinone, lipoic acid, lactoflavin, lutein, onion, rice bran, bamboo, carrot and hibiscus extract. Thus, the composition of the present invention comprising the substance can be used for anti-aging purposes by increasing skin elasticity and improving wrinkles.
The term "increasing skin elasticity" according to the present invention means that the composition of the present invention is used to enhance the structure of the subcutaneous fat layer of an individual in order to increase the elasticity of the skin. The skin may include any location of the skin of an individual, as long as the composition of the present invention can be used to increase elasticity or improve wrinkles.
The term "ameliorating" of the present invention refers to alleviating the symptoms of skin wrinkles in an individual using the compositions of the present invention.
One aspect of the present invention provides a cosmetic material composition for increasing elasticity of lip skin and improving wrinkles, comprising one or more selected from the group consisting of formononetin (Formononetin), emodin (Emodin), actellin C (Artepillin C), carnosic acid (Carnosic acid), palmitoamide (PALMITAMIDE), sodium guaazulenesulfonate (Sodium Guaiazulene Sulfonate), caffeic acid (CAFFEIC ACID), acetyl mandelic acid (ACETYL MANDELIC ACID), lacic acid (LACCAIC ACID), ubiquinone (Ubiquinone), hydroxycinnamic acid (Hydroxycinnamic Acid), xanthophylls (Xanthophyll), magnolia extract, aloe vera extract, fractions of magnolia extract, and fractions of aloe vera extract as an active ingredient.
One embodiment of the present invention may be a cosmetic composition for increasing skin elasticity of lips and improving wrinkles, which comprises one or more selected from the group consisting of magnolia bark extract and a fraction of magnolia bark extract.
Unlike other skin areas, the lips are free of sebaceous glands and have a very thin stratum corneum. Currently, most of the ingredients used to improve the volume of lips and wrinkles are applied to ingredients for improving dermis layers of skin, and the technology for improving subcutaneous fat layers occupying the largest volume in skin has a limitation that cannot be actively applied. In addition, from the viewpoint that penetration and transfer of an active ingredient are easier than other skin sites because the stratum corneum of the lips is very thin, a technique for improving the volume of the subcutaneous fat layer is expected to be a more effective technique in improving the volume and wrinkles. The composition of the present invention is characterized by having excellent effects on the lip skin as described above. In one embodiment of the present invention, magnolia bark extract was confirmed to have excellent wrinkle-improving effects on both the canthus and the lips, and was confirmed to have a higher improvement rate and improvement rate in the lips than in the canthus.
The cosmetic composition for lip skin may be manufactured in a dosage form selected from the group consisting of lipstick, lip gloss, and lip gloss, but is not limited thereto.
In the present invention, the cosmetic material composition may be manufactured in a dosage form selected from the group consisting of a solution, an external ointment, a skin cream, a foam, a nutritional lotion, a soft lotion, a mask, a soft water, an emulsion, a foundation, an essence, a soap, a liquid cleansing material, a bathing agent, a sun cream, a sun oil, a suspension, an emulsion, a paste, a gel, a skin lotion, a powder, a soap, a surfactant-containing cleansing cream, a skin oil, a powder foundation, an emulsion foundation, a wax foundation, a patch, and a spray, but is not limited thereto.
The cosmetic composition of the present invention may further contain one or more cosmetically acceptable carriers blended in general skin cosmetic materials, and may be appropriately mixed with, for example, oil, water, surfactants, moisturizers, lower alcohols, thickeners, chelating agents, pigments, preservatives, fragrances, and the like as usual ingredients, but is not limited thereto.
The cosmetically acceptable carrier contained in the cosmetic composition of the present invention varies depending on the formulation.
In the case where the dosage form of the present invention is an ointment, paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tragacanth, cellulose derivatives, polyethylene glycol, silicon, bentonite, silica, talc, zinc oxide or mixtures thereof can be used as a carrier component.
In the case where the dosage form of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder or a mixture thereof may be used as a carrier component, and in the case of a spray, a propellant such as chlorofluorocarbon, propane/butane or dimethyl ether may be further contained.
In the case where the dosage form of the present invention is a solution or emulsion, a solvent, a solubilizing agent or an emulsifier is used as a carrier component, and for example, water, ethanol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1, 3-butylene glycol oil, in particular, cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerin fatty acid ester, polyethylene glycol or fatty acid ester of sorbitol can be used.
In the case where the dosage form of the present invention is a suspension, a liquid diluent such as water, ethanol or propylene glycol may be used; suspending agents such as ethoxylated isostearyl alcohols, polyoxyethylene sorbitol esters, and polyoxyethylene sorbitol esters; microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, tragacanth, or the like as a carrier component.
In the case where the dosage form of the present invention is a soap, alkali metal salts of fatty acids, fatty acid half-ester salts, fatty acid protein hydrolysates, isethionates, lanolin derivatives, fatty alcohols, vegetable oils, glycerin, sugar and the like can be used as carrier components.
In addition to one or more selected from the group consisting of formononetin, emodin, atraprin C, carnosic acid, palmitoamide, guaiacol sodium sulfonate, caffeic acid, acetylmandelic acid, lachrymic acid, ubiquinone, hydroxycinnamic acid, xanthophylls, raspberry ketone (rasberry ketone), gallic acid (GALLIC ACID), terpineol, sodium mannose phosphate (sodium mannose phosphate), tolhenone (tropolone), glycyrrhetinic acid (GLYCYRRHETINIC ACID), lanosterol, sodium riboflavin phosphate (sodium riboflavin phosphate), menaquinone (menadione), lipoic acid (thioctic acid), lactoflavin (lactoflavin), onion extract, rice bran extract, bamboo extract, carrot extract, hibiscus extract, magnolia bark extract, aloe extract, and fractions of the extract, the cosmetic material composition of the present invention may contain commonly used adjuvants such as hydrophilic or lipophilic gelling agents, preserving agents, solvents, antioxidants, pigments, absorbents, and the like.
Another aspect of the present invention provides a food composition for increasing skin elasticity and improving wrinkles, comprising, as an active ingredient, one or more selected from the group consisting of formononetin, emodin, actirin C, carnosic acid, palmitomide, guaiacol sodium sulfonate, caffeic acid, acetyl mandelic acid, lachrymic acid, ubiquinone, hydroxycinnamic acid, xanthophylls, raspberry ketone (rasberry ketone), gallic acid (GALLIC ACID), terpineol, sodium mannose phosphate (sodium mannose phosphate), tolhenone (tropolone), glycyrrhetinic acid (GLYCYRRHETINIC ACID), lanosterol (lanosterol), riboflavin sodium phosphate (sodium riboflavin phosphate), menaquinone (menadione), lipoic acid (thioctic acid), lactoflavin (lactoflavin), onion extract, rice bran extract, bamboo extract, carrot extract, hibiscus extract, magnolia bark extract, aloe extract, and fractions of the extracts. In the present invention, the composition can increase skin elasticity and improve wrinkles by promoting differentiation of human fat-derived stem cells into adipocytes, or promoting proliferation of human fat-derived stem cells.
The increase and improvement of skin elasticity by formononetin, emodin, atrapilin C, carnosic acid, palmitoamide, guaiacol sodium sulfonate, caffeic acid, acetyl mandelic acid, laccaic acid, ubiquinone, hydroxycinnamic acid, xanthophylls, raspberry ketone (Raspberry ketone), gallic acid (GALLIC ACID), terpineol, sodium mannose phosphate (sodium mannose phosphate), tolhenone (tropolone), glycyrrhetinic acid (GLYCYRRHETINIC ACID), lanosterol, sodium riboflavin phosphate (sodium riboflavin phosphate), menaquinone (menadione), lipoic acid (thioctic acid), lactoflavin (lactoflavin), onion extract, rice bran extract, bamboo extract, carrot extract, hibiscus extract, magnolia bark extract, aloe vera extract and fractions of the extracts are as described above.
The present invention also provides a food composition for increasing skin elasticity and improving wrinkles, comprising formononetin, emodin, atrapilin C, carnosic acid, palmitoamide, guaiacol sodium sulfonate, caffeic acid, acetyl mandelic acid, lacic acid, ubiquinone, hydroxycinnamic acid, raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tolhenone, glycyrrhetinic acid, lanosterol, riboflavin sodium phosphate, menaquinone, lipoic acid, lactoflavin or lutein-based food acceptable salts as an active ingredient.
In the present invention, the "pharmaceutically acceptable salt" is in the form of formononetin, emodin, atpiclin C, carnosic acid, palmitamide, guaiacol sodium sulfonate, caffeic acid, acetyl mandelic acid, laccaic acid, ubiquinone, hydroxycinnamic acid, raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tolhenone, glycyrrhetinic acid, lanosterol, sodium riboflavin phosphate, menaquinone, lipoic acid, lactoflavin or a salt of lutein with other substances, and refers to substances capable of exhibiting similar activities to those of the compounds in the food.
The food composition of the present invention may contain a food auxiliary additive which is allowed in terms of food in addition to one or more selected from the group consisting of formononetin, emodin, actirin C, carnosic acid, palmitomide, guaiacol sodium sulfonate, caffeic acid, acetylmandelic acid, lachrymic acid, ubiquinone, hydroxycinnamic acid, xanthophylls, raspberry ketone (Raspberry ketone), gallic acid (GALLIC ACID), terpineol, sodium mannose phosphate (sodium mannose phosphate), tolhenone (tropolone), glycyrrhetinic acid (GLYCYRRHETINIC ACID), lanosterol, riboflavin sodium phosphate (sodium riboflavin phosphate), menaquinone (menadione), lipoic acid (thioctic acid), lactoflavin (lactoflavin), onion extract, rice bran extract, bamboo extract, carrot extract, hibiscus extract, magnolia bark extract, aloe extract and fractions of the extract.
In the present invention, the "food auxiliary additive" means a component that can be added to a food in an auxiliary manner, and is added at the time of manufacturing a health functional food in various dosage forms, and can be used by a person skilled in the art by appropriate selection. As examples of the food auxiliary additives, various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavors and natural flavors, coloring agents and fillers, pectic acids and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated beverages, and the like are included, but not limited thereto.
The functional food composition of the present invention may include a health functional food. In the present invention, the "health functional food" refers to a food manufactured and processed in the form of tablets, capsules, powders, granules, liquids, pellets, and the like using raw materials or ingredients having a function useful for the human body. The term "functional" as used herein means that it has beneficial effects on the structure and function of the human body, regulating nutrients, or on the physiological effects of health care. The health functional food of the present invention can be manufactured by a method commonly used in the art, and can be manufactured by adding raw materials and ingredients commonly added in the art at the time of manufacture. In addition, the formulation of the health functional food can be manufactured without limitation as long as it is considered as a formulation of the health functional food. The food composition of the present invention can be manufactured in various forms of dosage forms, and unlike general medicines, uses foods as raw materials, thereby having advantages of no side effects or the like caused by long-term administration, and is excellent in portability, so that the health functional food of the present invention can be ingested as an adjuvant for increasing skin elasticity and improving wrinkles.
The health functional food of the present invention may take any form including all foods in the conventional sense, and may be used in combination with terms known in the art such as functional foods. The health functional food of the present invention can be produced by mixing other auxiliary components, which may be contained in the food, with known additives according to the choice of those skilled in the art. Examples of foods that can be added include meats, sausages, breads, chocolates, candies, snacks, biscuits, pizzas, stretched noodles, other noodles, chewing gums, ice cream, various soups, beverages, teas, oral liquids, alcoholic beverages, vitamin complex agents, and the like. In addition, food products for use as animal feed are included.
Another aspect of the present invention provides a pharmaceutical composition for increasing skin elasticity and improving wrinkles, comprising, as an active ingredient, one or more selected from the group consisting of formononetin, emodin, actirin C, carnosic acid, palmitomide, guaiacol sodium sulfonate, caffeic acid, acetyl mandelic acid, lachrymic acid, ubiquinone, hydroxycinnamic acid, xanthophylls, raspberry ketone (rasberry ketone), gallic acid (GALLIC ACID), terpineol, sodium mannose phosphate (sodium mannose phosphate), tolhenone (tropolone), glycyrrhetinic acid (GLYCYRRHETINIC ACID), lanosterol (lanosterol), riboflavin sodium phosphate (sodium riboflavin phosphate), menaquinone (menadione), lipoic acid (thioctic acid), lactoflavin (lactoflavin), onion extract, rice bran extract, bamboo extract, carrot extract, hibiscus extract, magnolia bark extract, aloe extract, and fractions of the extracts. In the present invention, the composition can increase skin elasticity and improve wrinkles by promoting differentiation of human fat-derived stem cells into adipocytes. The increase and improvement of skin elasticity of formononetin, emodin, actirin C, carnosic acid, palmitoamide, guaiacol sodium sulfonate, caffeic acid, acetyl mandelic acid, lacic acid, ubiquinone, hydroxycinnamic acid, xanthophylls, magnolia officinalis, aloe vera, extracts, fractions are as described above.
In addition, the present invention provides a pharmaceutical composition for increasing skin elasticity and improving wrinkles, comprising formononetin, emodin, atraprin C, carnosic acid, palmitoamide, guaiacol sodium sulfonate, caffeic acid, acetyl mandelic acid, lacic acid, ubiquinone, hydroxycinnamic acid or a pharmaceutically acceptable salt of lutein as an active ingredient.
In the present invention, the "pharmaceutically acceptable salt" is in the form of formononetin, emodin, atpiclin C, carnosic acid, palmitoamide, guaiacol sodium sulfonate, caffeic acid, acetyl mandelic acid, laccaic acid, ubiquinone, hydroxycinnamic acid, raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tolhenone, glycyrrhetinic acid, lanosterol, riboflavin sodium phosphate, menaquinone, lipoic acid, lactoflavin or a salt of lutein with other substances, and refers to substances capable of exhibiting similar activities to those of the compounds in the pharmaceutical sense.
The pharmaceutical composition of the present invention may be used as a single preparation, may be used as a composite preparation further comprising a known drug having skin elasticity enhancing and wrinkle improving effects, and may be formulated with a pharmaceutically acceptable carrier or excipient to be manufactured in a unit-capacity form, or may be manufactured by being put into a multi-capacity container.
The pharmaceutical composition may be administered in a pharmaceutically effective dose. By "pharmaceutically effective dose" is meant an amount sufficient to treat a disease at a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level may be determined based on factors including the type and severity of the individual, age, sex, activity of the drug, sensitivity to the drug, time of administration, route of administration and rate of excretion, the course of treatment, the factors of the drug being used concurrently, and other factors well known in the medical arts.
Another aspect of the present invention provides a pharmaceutical external composition for increasing skin elasticity and improving wrinkles, comprising one or more selected from the group consisting of formononetin, emodin, atraylin C, carnosic acid, palmitomide, guaiacol sodium sulfonate, caffeic acid, acetyl mandelic acid, lachrymic acid, ubiquinone, hydroxycinnamic acid, xanthophylls, raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tolhenone, glycyrrhetinic acid, lanosterol, sodium riboflavin phosphate, menaquinone, lipoic acid, lactoflavin, onion extract, rice bran extract, bamboo extract, carrot extract, hibiscus extract, magnolia bark extract, aloe extract, and fractions of the extracts as an active ingredient. In the present invention, the composition can increase skin elasticity and improve wrinkles by promoting differentiation of human fat-derived stem cells into adipocytes. The increase and improvement of skin elasticity by formononetin, emodin, actellin C, carnosic acid, palmitoamide, guaiacol sodium sulfonate, caffeic acid, acetyl mandelic acid, lacc acid, ubiquinone, hydroxycinnamic acid, xanthophylls, raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tolhenone, glycyrrhetinic acid, lanosterol, riboflavin sodium phosphate, menaquinone, lipoic acid, lactoflavin, onion, rice bran, bamboo, carrot, hibiscus, magnolia bark, aloe vera, extracts, fractions are as described above.
The present invention also provides a pharmaceutical external composition for increasing skin elasticity and improving wrinkles, comprising formononetin, emodin, atrapilin C, carnosic acid, palmitoamide, guaiacol sodium sulfonate, caffeic acid, acetyl mandelic acid, lacic acid, ubiquinone, hydroxycinnamic acid, raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tolhenone, glycyrrhetinic acid, lanosterol, riboflavin sodium phosphate, menaquinone, lipoic acid, lactoflavin or a pharmaceutically acceptable salt of lutein as an active ingredient. The "pharmaceutically acceptable salts" are as described above.
In addition to the above-mentioned components, the pharmaceutical external composition of the present invention may contain a pharmaceutically acceptable carrier, excipient or diluent as required. The pharmaceutically acceptable carrier, excipient or diluent is not limited as long as the effect of the present invention is not impaired, and may include, for example, fillers, extenders, binders, wetting agents, disintegrants, surfactants, lubricants, sweeteners, fragrances, preservatives, and the like.
The "pharmaceutically acceptable carrier" may refer to a carrier, excipient or diluent which does not stimulate an organism and does not hinder the biological activity and properties of the compound to be injected, and in particular may be a non-natural carrier (non-naturally occuring carrier). The type of the carrier that can be used in the present invention is not particularly limited, and any pharmaceutically acceptable carrier commonly used in the art can be used. As non-limiting examples of the carrier, physiological saline, sterile water, ringer's solution, buffered physiological saline, albumin injection, dextrose solution, maltose solution, glycerin, ethanol, and the like can be given. These carriers may be used alone, or two or more kinds may be mixed and used.
The composition comprising a pharmaceutically acceptable carrier may be in various dosage forms, whether oral or non-oral. In the case of formulation, the composition is prepared by using a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, etc., which are generally used. Specifically, solid preparations for oral administration include tablets, pills, powders, granules, capsules and the like, which can be prepared by mixing at least one or more excipients such as starch, calcium carbonate, sucrose, lactose, gelatin and the like in the compound. In addition, lubricants such as magnesium stearate and talc may be used in addition to simple excipients. Liquid preparations for oral administration are suspensions, oral solutions, emulsions, syrups and the like, and may include various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like, in addition to water and liquid paraffin as simple diluents commonly used. Formulations for non-oral administration include sterile aqueous solutions, nonaqueous solvents, suspensions, emulsions, lyophilized formulations, and suppositories. As the nonaqueous solvent and suspending agent, vegetable oils such as propylene glycol, polyethylene glycol and olive oil, and injectable esters such as ethyl oleate and the like can be used. As a base for suppositories, WITEPSOL, polyethylene glycol (Macrogol), tween 61, cocoa butter, laurate, glycerogelatin, and the like can be used.
Examples of the pharmaceutical external composition of the present invention include, but are not limited to, a disinfectant cleanser, bath foam, ointment, wet tissues, and coating agent, and the method of preparing the pharmaceutical external composition, the dosage, the method of use, and the constituent components may be appropriately selected from common techniques known in the art.
In addition, the pharmaceutical topical composition of the present invention may be used in a method of improving skin wrinkles, the method comprising the step of applying the pharmaceutical topical composition of the present invention to the skin of an individual. Such individuals include, but are not limited to, mammals including mice, livestock, humans, and the like.
In still another aspect, the present invention provides a composition for promoting differentiation of stem cells derived from human fat, comprising as an active ingredient one or more selected from the group consisting of formononetin, emodin, actellin C, carnosic acid, palmitomide, guaiacol sodium sulfonate, caffeic acid, acetylmandelic acid, lachrymic acid, ubiquinone, hydroxycinnamic acid, xanthophylls, raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tolhenone, glycyrrhetinic acid, lanosterol, sodium riboflavin phosphate, menaquinone, lipoic acid, lactoflavin, onion extract, rice bran extract, bamboo extract, carrot extract, hibiscus extract, magnolia extract, aloe extract, fractions of magnolia extract, and fractions of aloe extract. In the present invention, the composition can increase skin elasticity and improve wrinkles by promoting differentiation of human fat-derived stem cells into adipocytes. The increase and improvement of skin elasticity by formononetin, emodin, actellin C, carnosic acid, palmitoamide, guaiacol sodium sulfonate, caffeic acid, acetyl mandelic acid, lacc acid, ubiquinone, hydroxycinnamic acid, xanthophylls, raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tolhenone, glycyrrhetinic acid, lanosterol, riboflavin sodium phosphate, menaquinone, lipoic acid, lactoflavin, onion, rice bran, bamboo, carrot, hibiscus, magnolia bark, aloe vera, extracts, fractions are as described above.
Yet another aspect of the present invention provides a method of increasing skin elasticity comprising the step of administering the composition to an individual other than a human.
The term "administration" as used herein refers to the administration of the compositions of the present invention to a patient by any suitable method, the route of administration of the compositions being by any general route that is capable of reaching the target tissue. The drug may be administered intraperitoneally, intravenously, intramuscularly, subcutaneously, intradermally, orally, topically, intranasally, but is not limited thereto. Since the composition of the present invention has the characteristics of having the effect of increasing skin elasticity and improving wrinkles, the administration route of the composition may be administration by applying to the skin.
The composition of the present invention may be administered daily or intermittently, or the number of daily administrations may be divided into 1 or 2 to 3. In addition, the composition of the present invention may be used alone or in combination with other drug treatments in order to increase skin elasticity and improve wrinkles. In view of all the above, it is important that the administration can be performed in an amount that achieves the maximum effect in a minimum amount without side effects, and the amount can be easily determined by one skilled in the art.
The term "individual" as used herein refers to all animals including mice, domestic animals, etc. that may develop reduced skin elasticity or wrinkles. Specifically, the present invention may be a mammal including a human.
Embodiment(s)
Hereinafter, the present invention will be described in detail by way of the following examples. The following examples are merely illustrative of the present invention and the scope of the present invention is not limited by the following examples.
Example 1: preparation method of Magnolia bark extract and aloe extract
The magnolia bark extract of this example was purchased from korea bleacher (kyo corporation, hua Cheng, korea), and after dissolving powder of magnolia bark (Magnoliae Cortex) in a solvent such as dipropylene glycol (DPG), dimethyl sulfoxide (DMSO), etc., the mixture was filtered through a0.2 μm syringe filter, and the filtered liquid was used as the magnolia bark extract.
To make the Aloe extract of this example, aloe (Aloe Vera) was purchased from korean domestic farms and extracted once with 70% methanol at a ratio of 1:10 at 70 ℃.
Example 2: confirming the effect of formononetin, acetyl mandelic acid and Magnolia officinalis extract on promoting differentiation of human fat-derived stem cells
Human adipose derived stem cells (Human adipose DERIVED STEM CELL) were purchased from Lonza Inc. (Lonza Inc, walkersvile, MD, USA) and cultured according to the Ind guidelines of Lonza Inc. Experiments were performed on whether to differentiate into adipocytes using the differentiation medium recommended by the Dragon's Corp. As a positive control group, differentiation medium was treated with Rosiglitazone (Rosiglitazone) 1 uM. To induce differentiation of adipose-derived stem cells into adipocytes, after starting culturing the cells for 3 to 5 days, the cell culture solution was removed, and the positive control group was treated with formononetin, acetyl mandelic acid, and magnolia bark extract for 14 days.
After 14 days from the start of differentiation into adipocytes, the cell culture solution was removed, the cells were washed with phosphate buffer (DPBS), and then the cells were fixed using 10% formalin. Lipids within the differentiated adipocytes were stained with Oil Red O (Oil Red O) to visualize the fixed cells with a microscope. As a result, it was found that the differentiation effect of adipose-derived stem cells into adipocytes was excellent in the case of treatment with formononetin (Formononetin), acetyl mandelic acid (ACETYL MANDELIC ACID) and magnolia officinalis extract as representative substances, compared with the case of treatment with differentiation medium alone (negative control group) (fig. 1).
Example 3: quantitative confirmation of the effect of 12 compounds including formononetin, magnolia bark extract and aloe extract on promoting differentiation of human fat-derived stem cells
In the same manner as in example 2 above, after the cultured human fat-derived stem cells were treated with 12 compounds including formononetin, magnolia bark extract and aloe extract, oil red O for staining was eluted with 100% isopropyl alcohol solution, and then absorbance was measured at a wavelength of 490nm and quantified, the results of which are shown in fig. 2. From this, it was confirmed that 14 substances including formononetin of the present invention respectively showed a significant increase in the relative differentiation rate as compared with the negative control group treated with only the differentiation medium, thereby promoting differentiation of adipose-derived stem cells into adipocytes, and being able to effectively promote differentiation into adipocytes as compared with an undifferentiated material such as kaempferol (kaempherol). Thus, the composition of the present invention comprising the substance can be used as an anti-aging purpose for increasing skin elasticity and improving wrinkles by promoting differentiation of adipose-derived stem cells and increasing subcutaneous fat cells.
Example 4: confirming the effect of Magnolia bark extract on improving skin wrinkles of lips
In order to confirm the effect of the magnolia bark extract produced in the above example 1 on improving skin wrinkles, the skin of lips and skin under eyes of subjects (total number of subjects: 12) were treated with the magnolia bark extract.
Wrinkles of the lip skin were measured by taking a jacus photograph to designate the most convex portion of the lower lip of a certain length and finding the standard deviation of the shading value. It was confirmed that the standard deviation of the shading value ranges from 3 to 12, and the more wrinkles, the larger the standard deviation. The wrinkles of the skin under the eyes were measured by taking a picture of knuds using a wrinkle analysis program in knuds, i.e., by calculating the area of the wrinkles. It was confirmed that the value of the wrinkles was in the range of 7 to 44.
The results of the change in the lip wrinkle value of 1 or more and the change in the under-eye wrinkle value of 4 or more were classified as improved result values. The classification criterion was selected because a numerical value capable of clearly distinguishing whether improvement was found with the naked eye, that is, a lip wrinkle of 2 and a sub-eye wrinkle of 8 was confirmed, and a 1/2 value of the numerical value was selected as a criterion for judging whether improvement was found.
Treatment of the lip skin with magnolia bark extract confirmed improvement from week 4, while the number of subjects improved at week 8 (8) reached a maximum, and confirmed that they remained similar until week 12. As a result of the treatment of the under-eye wrinkles with the magnolia bark extract, it was confirmed that improvement was achieved by the 4 th week at a similar rate to the lip skin, and the number of subjects improved by the 12 th week continued to increase although the rate of rise was low (fig. 3).
In addition, it was confirmed that after the treatment of the subject's lip skin with magnolia bark extract, the wrinkle-improving effect was continued until week 12, and the elasticity of the lip skin was improved (fig. 4). This is a result of confirming that magnolia bark extract actually has an effect of improving wrinkles and elasticity of skin by promoting differentiation of adipose stem cells and increasing subcutaneous adipocytes.
As a result of comparing the effect of asiaticoside, which is a conventional wrinkle-improving material, on the improvement of wrinkles of lip skin and under-eye skin, it was confirmed that the improvement rate and improvement rate of wrinkles of lip skin by magnolia officinalis extract were more excellent than those of under-eye skin, whereas the improvement rate and improvement rate of wrinkles of under-eye skin by asiaticoside were more excellent than those of lip skin (fig. 5).
Thus, the magnolia bark extract has a skin wrinkle-improving effect, and particularly, has a more excellent effect of improving wrinkles of lip skin.
Example 5: preparation method of extract of onion, rice bran, bamboo, carrot and hibiscus
In the present invention, the extracts of onion, rice bran, bamboo, carrot and hibiscus are extracted with methanol, respectively, and then these extracts are dried to be made into powder form for use.
Example 6: confirming the effect of the compounds and extracts on promoting proliferation of human fat-derived stem cells
After purchasing human adipose stem cells (human adipose DERIVED STEM CELLS) from Lonza corporation (Lonza, inc.Walkersville, MD, USA), the cells were cultured in carbon dioxide medium at 37 degrees celsius under 5% carbon dioxide. After each material was treated at concentrations of 0.2ppm, 2ppm, and 20ppm, the degree of cell activity of human adipose-derived stem cells was confirmed using the CCK-8 kit (Dojindo: tonic chemical). As a result, each material showed the highest activity at the concentration of table 1 below, and all materials showed a cell activity rate higher by 20% or more than that of the untreated group (control group) (fig. 6).
TABLE 1
Material name Concentration of
Lutein (lutein) 20ppm
Lactoflavin 20ppm
Lipoic acid (lipoic acid) 20ppm
Menadione (R) quinone 0.2ppm
Riboflavin sodium phosphate 20ppm
Lanosterol 2ppm
Glycyrrhetinic acid 20ppm
Mannose phosphate sodium salt 2ppm
Tocopolone 2ppm
Terpineol (SONGYL) 20ppm
Carnosic acid 2ppm
Caffeic acid 20ppm
Gallic acid 20ppm
Raspberry ketone 20ppm
Onion (onion) 2ppm
Rice bran 20ppm
Bamboo 2ppm
Carrot (carrot) 20ppm
Hibiscus syriacus (L.) Sa 20ppm
Thus, the total of 19 compounds or extracts of the present invention significantly promote proliferation of stem cells derived from human fat, and thus can be used for anti-aging purposes by increasing skin elasticity and improving wrinkles.
From the above description, it should be understood by those skilled in the art that the present invention may be embodied in other specific forms without changing the technical spirit or essential characteristics. In this connection, the above-described embodiments are exemplary in all respects, and should be construed as non-limiting. The scope of the invention should be construed as including all changes and modifications to the appended claims, as well as all equivalents thereof, rather than the foregoing detailed description.

Claims (14)

1. Use of a cosmetic composition comprising as an active ingredient one or more substances selected from the group consisting of guaiac sodium sulfonate, acetyl mandelic acid, lacic acid, and palmitoamide for increasing skin elasticity and improving wrinkles.
2. The use according to claim 1, wherein,
The skin is lip skin and the wrinkles are lip wrinkles.
3. The use according to claim 1, wherein,
The cosmetic composition is formulated into a dosage form selected from lipstick, lip gloss or lip balm.
4. The use according to claim 1, wherein,
The cosmetic material composition comprises guaiac sodium azulene sulfonate, or acetyl mandelic acid, or lacic acid, or a cosmetically acceptable salt of palmitoamide as an active ingredient.
5. The use according to claim 1, wherein,
Comprising from 0.0001 to 10% by weight of said substance, relative to the total weight of the cosmetic composition.
6. The use according to claim 1, wherein,
The substance promotes differentiation of stem cells derived from human fat into adipocytes.
7. The use according to claim 1, wherein,
The composition is in the form of a soft lotion, i.e. a nutritional lotion, astringent lotion, nutritional cream, massage cream, essence, facial mask, skin patch, skin-adhering gel, powder, ointment, suspension, emulsion, spray or cosmetic liquid.
8. Use of a pharmaceutical composition comprising as active ingredient one or more substances selected from the group consisting of guaiac sodium sulfonate, acetyl mandelic acid, lacic acid, and palmitoamide for increasing skin elasticity and improving wrinkles.
9. The use according to claim 8, wherein,
The skin is lip skin and the wrinkles are lip wrinkles.
10. The use according to claim 8, wherein,
The pharmaceutical composition comprises palmitamide, guaiac sodium sulfonate, acetyl mandelic acid, or pharmaceutically acceptable salt of lacic acid as an active ingredient.
11. Use of a composition comprising as active ingredient one or more substances selected from the group consisting of sodium guaiacol sulfonate, acetyl mandelic acid, lacic acid, and palmitoamide for the manufacture of a pharmaceutical external composition for increasing skin elasticity and improving wrinkles.
12. The use according to claim 11, wherein,
The skin is lip skin and the wrinkles are lip wrinkles.
13. The use according to claim 11, wherein,
The pharmaceutical external composition comprises guaiac sodium azulene sulfonate, or acetyl mandelic acid, or lacic acid, or pharmaceutically acceptable salts of palmitoyl amide as an active ingredient.
14. Use of a composition comprising as active ingredient one or more substances selected from the group consisting of sodium guaiac acid, acetyl mandelic acid, lacic acid, and palmitoyl amide for promoting differentiation of human adipose-derived stem cells.
CN202410183350.XA 2018-08-23 2019-08-23 Composition for promoting differentiation or proliferation of human adipose-derived stem cells Pending CN118021632A (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
KR20180098717 2018-08-23
KR10-2018-0098717 2018-08-23
KR1020180109108A KR102311011B1 (en) 2018-09-12 2018-09-12 A composition for promoting the proliferation of human adipose derived stem cell
KR10-2018-0109108 2018-09-12
KR1020190029998A KR102199678B1 (en) 2018-08-23 2019-03-15 A composition for promoting the differentiation of human adipose derived stem cell
KR10-2019-0029998 2019-03-15
PCT/KR2019/010815 WO2020040621A1 (en) 2018-08-23 2019-08-23 Composition for promoting differentiation or proliferation of human adipose stem cells
CN201980055771.1A CN112638357B (en) 2018-08-23 2019-08-23 Composition for promoting differentiation or proliferation of human fat-derived stem cells

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980055771.1A Division CN112638357B (en) 2018-08-23 2019-08-23 Composition for promoting differentiation or proliferation of human fat-derived stem cells

Publications (1)

Publication Number Publication Date
CN118021632A true CN118021632A (en) 2024-05-14

Family

ID=69593327

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202410183350.XA Pending CN118021632A (en) 2018-08-23 2019-08-23 Composition for promoting differentiation or proliferation of human adipose-derived stem cells

Country Status (3)

Country Link
JP (2) JP2021535208A (en)
CN (1) CN118021632A (en)
WO (1) WO2020040621A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022169246A1 (en) * 2021-02-02 2022-08-11 주식회사 엘지생활건강 Cosmetic material composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060070A (en) * 1997-06-11 2000-05-09 Gorbach; Sherwood L. Isoflavonoids for treatment and prevention of aging skin and wrinkles
JP5063947B2 (en) * 2006-07-18 2012-10-31 株式会社ナリス化粧品 Acrolein adduct formation inhibitor, and skin anti-aging external preparation and anti-aging food and drink containing the same
KR100844516B1 (en) * 2007-02-12 2008-07-08 주식회사 사임당화장품 Cosmetic composition containing astragalus root extract
KR20130037563A (en) * 2011-10-06 2013-04-16 (주)아모레퍼시픽 Compositions containing an extract of machilus thunbergii siebold zuccarini for anti-aging through activation of retinoic acid receptor

Also Published As

Publication number Publication date
JP2021535208A (en) 2021-12-16
WO2020040621A1 (en) 2020-02-27
JP2024009897A (en) 2024-01-23

Similar Documents

Publication Publication Date Title
EP3334501B1 (en) Compositions including ampelopsis grossedentata and albizia julibrissin extracts and methods of use
TWI381834B (en) Abnormal protein removal composition
KR101387308B1 (en) Skin whitening composition by using of dendropanax morbifera ferment extract
KR102113193B1 (en) Composition for improving skin conditions comprising artemisiae annuae herba, centella asiatica and green tea extract or fraction thereof and method for improving skin conditions using the same
CN111053716A (en) Application of Fuzhuan tea extract in preparation of skin conditioning product
KR101829892B1 (en) A cosmetic composition comprising fraxinus rhynchophylla extract and calystegia soldanella extract
KR20100010316A (en) Cosmetic composition for preventing skin aging
KR101825704B1 (en) A cosmetic composition comprising coffee silver skin extract
JP2024009897A (en) Composition for promoting differentiation or proliferation of human adipose-derived stem cell
JP6709783B2 (en) Composition for preventing hair loss or promoting hair growth containing alpine wormwood extract
KR101829891B1 (en) A cosmetic composition comprising osmanthus asiaticus extract and clematis apiifolia extract
KR20170137465A (en) Composition for improving skin condition comprising herb extracts mixture
KR101009766B1 (en) Cosmetic Composition containing the Extract of prunella vulgaris and Artemisia abrotanum for Improvement of Wrinkle
CN112638357B (en) Composition for promoting differentiation or proliferation of human fat-derived stem cells
KR20120139222A (en) Composition for skin external application comprising tanshinone iia as the active ingredient
KR102184155B1 (en) A composition for promoting the differentiation of human adipose derived stem cell
TWI706792B (en) Use of skunk cabbage extract or its fraction
KR102503007B1 (en) A composition for promoting the differentiation of human adipose derived stem cell
KR102162935B1 (en) Cosmetic composition for skin suppression, skin moisturizing, anti-acne or sebum controlling
KR20170137405A (en) Composition for improving skin condition comprising herb extracts mixture
KR20190130543A (en) Composition for improving wrinkle comprising Symplocarpus foetidus extract or fractions thereof
KR20170137412A (en) Composition for improving skin condition comprising herb extracts mixture
KR102311011B1 (en) A composition for promoting the proliferation of human adipose derived stem cell
JP6022333B2 (en) Ceramide production promoter
KR20190027179A (en) A cosmetic composition comprising arenaria serpyllifolia extract

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination